Home/Pipeline/MO-825

MO-825

Atopic Dermatitis

Phase 3Active - Pivotal Trials

Key Facts

Indication

Atopic Dermatitis

Phase

Phase 3

Status

Active - Pivotal Trials

Company

Mochida Pharmaceutical

About Mochida Pharmaceutical

Mochida Pharmaceutical is a mission-driven company focused on contributing to human health through the creation of innovative pharmaceuticals. It has achieved a dominant position in the Japanese market with a diversified portfolio and a robust, fully integrated operational model. Its core strategy balances the steady cash flows from its consumer healthcare and diagnostic businesses with targeted R&D investments in novel prescription drugs, supplemented by strategic global partnerships to access new technologies and markets. With a market capitalization of $127.8 billion, it represents a cornerstone of stability and long-term value in the biopharmaceutical sector.

View full company profile

Therapeutic Areas

Oncology Immunology & Inflammation Dermatology Gastroenterology

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active